Literature DB >> 24778162

Myeloid-derived suppressor cells in the development of lung cancer.

Myrna L Ortiz1, Lily Lu, Indu Ramachandran, Dmitry I Gabrilovich.   

Abstract

Myeloid-derived suppressor cells (MDSC) are widely implicated in immune suppression associated with tumor progression and chronic inflammation. However, very little is known about their possible role in tumor development. Here, we evaluated the role of MDSC in two experimental models of lung cancer: inflammation-associated lung cancer caused by chemical carcinogen urethane in combination with exposure to cigarette smoke; and a transgenic CC10Tg model not associated with inflammation. Exposure of mice to cigarette smoke alone resulted in significant accumulation in various organs of cells with typical MDSC phenotype (Gr-1(+)CD11b(+)). However, these cells lacked immunosuppressive activity and could not be defined as MDSC. When cigarette smoke was combined with a single dose of urethane, it led to the development of tumor lesions in lungs within 4 months. By that time, Gr-1(+)CD11b(+) cells accumulated in the spleen and lung and had potent immunosuppressive activity, and thus could be defined as MDSC. In the CC10Tg model, accumulation of immunosuppressive MDSC was observed only at 4 months of age, after the appearance of tumor lesions in the lungs. Accumulation of MDSC in both models was abrogated in S100A9 knockout mice. This resulted in a dramatic improvement in survival of mice in both models. Thus, cigarette smoke results in the expansion of immature myeloid cells lacking suppressive activity. Accumulation of bona fide MDSC in both models was observed only after the development of tumor lesions. However, MDSC played a major role in tumor progression and survival, which suggests that their targeting may provide clinical benefits in lung cancer. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24778162      PMCID: PMC4007346          DOI: 10.1158/2326-6066.CIR-13-0129

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  38 in total

1.  Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis.

Authors:  Lori R Kisley; Bradley S Barrett; Alison K Bauer; Lori D Dwyer-Nield; Benjamin Barthel; Amy M Meyer; David C Thompson; Alvin M Malkinson
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

2.  Cyclin-dependent kinase inhibitor expression in pulmonary Clara cells transformed with SV40 large T antigen in transgenic mice.

Authors:  S M Magdaleno; G Wang; V L Mireles; M K Ray; M J Finegold; F J DeMayo
Journal:  Cell Growth Differ       Date:  1997-02

3.  Prognostic impact of S100A9 overexpression in non-small cell lung cancer.

Authors:  Hideki Kawai; Yoshihiro Minamiya; Naoko Takahashi
Journal:  Tumour Biol       Date:  2011-03-03

4.  v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid.

Authors:  A Leder; A Kuo; R D Cardiff; E Sinn; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 5.  Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Authors:  Lisa M Coussens; Laurence Zitvogel; A Karolina Palucka
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

6.  Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins.

Authors:  Linda Wang; Esther W Y Chang; Siew Cheng Wong; Siew-Min Ong; Debra Q Y Chong; Khoon Lin Ling
Journal:  J Immunol       Date:  2012-12-17       Impact factor: 5.422

Review 7.  The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer.

Authors:  Jan M Ehrchen; Cord Sunderkötter; Dirk Foell; Thomas Vogl; Johannes Roth
Journal:  J Leukoc Biol       Date:  2009-05-18       Impact factor: 4.962

8.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

Review 9.  History of myeloid-derived suppressor cells.

Authors:  James E Talmadge; Dmitry I Gabrilovich
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

10.  Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.

Authors:  Indu R Ramachandran; Anna Martner; Alexandra Pisklakova; Thomas Condamine; Tess Chase; Thomas Vogl; Johannes Roth; Dmitry Gabrilovich; Yulia Nefedova
Journal:  J Immunol       Date:  2013-03-04       Impact factor: 5.422

View more
  50 in total

1.  Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients.

Authors:  Marta Usó; Eloísa Jantus-Lewintre; Silvia Calabuig-Fariñas; Ana Blasco; Eva García Del Olmo; Ricardo Guijarro; Miguel Martorell; Carlos Camps; Rafael Sirera
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

2.  Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation.

Authors:  Jingjiao Zhou; Zhaoxia Qu; Fan Sun; Lei Han; Liwen Li; Shapei Yan; Laura P Stabile; Lin-Feng Chen; Jill M Siegfried; Gutian Xiao
Journal:  Cancer Immunol Res       Date:  2017-01-20       Impact factor: 11.151

3.  Lactoferrin deficiency induces a pro-metastatic tumor microenvironment through recruiting myeloid-derived suppressor cells in mice.

Authors:  Lingyu Wei; Xuemei Zhang; Jia Wang; Qiurong Ye; Xiang Zheng; Qiu Peng; Ying Zheng; Peishan Liu; Xiaoyue Zhang; Zhengshuo Li; Can Liu; Qun Yan; Guiyuan Li; Jian Ma
Journal:  Oncogene       Date:  2019-08-28       Impact factor: 9.867

Review 4.  Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.

Authors:  Tomonori Yaguchi; Yutaka Kawakami
Journal:  Int Immunol       Date:  2016-07-08       Impact factor: 4.823

5.  Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.

Authors:  Lillian Sun; Paul E Clavijo; Yvette Robbins; Priya Patel; Jay Friedman; Sarah Greene; Rita Das; Chris Silvin; Carter Van Waes; Lucas A Horn; Jeffrey Schlom; Claudia Palena; Dean Maeda; John Zebala; Clint T Allen
Journal:  JCI Insight       Date:  2019-04-04

6.  Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells.

Authors:  Y Lai; J Weng; X Wei; L Qin; P Lai; R Zhao; Z Jiang; B Li; S Lin; S Wang; Q Wu; Z Tang; P Liu; D Pei; Y Yao; X Du; P Li
Journal:  Leukemia       Date:  2017-08-03       Impact factor: 11.528

7.  Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer.

Authors:  Pauline L de Goeje; Koen Bezemer; Marlies E Heuvers; Anne-Marie C Dingemans; Harry Jm Groen; Egbert F Smit; Henk C Hoogsteden; Rudi W Hendriks; Joachim Gjv Aerts; Joost Pjj Hegmans
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

8.  Myeloid-derived suppressor cells enhance the expression of melanoma-associated antigen A4 in a Lewis lung cancer murine model.

Authors:  Guilan Shi; Huiru Wang; Xiufen Zhuang
Journal:  Oncol Lett       Date:  2015-11-13       Impact factor: 2.967

Review 9.  Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation.

Authors:  Jonathan E Schoenhals; Steven N Seyedin; Clark Anderson; Eric D Brooks; Yun R Li; Ahmed I Younes; Sharareh Niknam; Ailin Li; Hampartsoum B Barsoumian; Maria Angelica Cortez; James W Welsh
Journal:  Transl Lung Cancer Res       Date:  2017-04

10.  Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.

Authors:  Benedetto Farsaci; Renee N Donahue; Michael A Coplin; Italia Grenga; Lauren M Lepone; Alfredo A Molinolo; James W Hodge
Journal:  Cancer Immunol Res       Date:  2014-08-04       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.